Vir Biotechnology Inc (VIR)

Viral Hepatitis · registered primary completion 2026-12-01 · NCT07128550

Published 2026-09-02Market cap $1,833M7 sourced statements

A Study to Evaluate Tobevibart+Elebsiran in Participants With Chronic HDV Infection Not Virologically Suppressed With Bulevirtide · PHASE3 · n=150 · active not recruiting

Runway

fact

Cash of $529M against operating outflow of $88M per quarter gives roughly 6.0 quarters of runway, clearing the registered primary completion 1.1 quarters out by 4.9 quarters.

Source: 10-Q filed 2026-08-05

Share count and dilution

fact

169,215,958 shares outstanding against 179,589,293 if every outstanding option, warrant and convertible were exercised. In that case 5.8% of a gain in enterprise value would accrue to those holders rather than to current shareholders.

Source: antidilutive-securities disclosure, 10-Q filed 2026-08-05

Market

fact

No approved product carries Viral Hepatitis on label.

Source: FDA label index

Trial registry

fact

Registered design for NCT07128550: randomized, open-label, 150 participants (estimated). Primary outcome: HDV RNA < Lower Limit of Quantification (LLOQ), Target not detected (TND) at Week 24. 1 further primary outcome(s) registered.

Source: ClinicalTrials.gov record

Regulatory

fact

Designations disclosed: Breakthrough Therapy, Fast Track, Orphan Drug, PRIME (EU). These accelerate review and, for Orphan, confer exclusivity if approved; none is evidence of efficacy.

Source: 10-Q filed 2026-08-05

Pipeline

fact

7 distinct molecules in 7 active company-sponsored trials; Tobevibart accounts for 3 of them at Phase 2/Phase 3.

Source: ClinicalTrials.gov, company as lead sponsor

Ownership and proceedings

fact

Directors and executive officers as a group hold 2.9%.

Source: DEF 14A filed 2026-04-16

This sheet is dated and will not be edited. When the registered primary completion passes, its outcome is recorded on the scoreboard and a new dated sheet is published if the filings change materially.